Applied BioMath, LLC
Quantitative systems pharmacology (QSP) simulation platform for predicting immunocytokine dose, pharmacokinetics, and therapeutic window
- Sector
- Biotech
- Headquarters
- Concord, MA
- Founded
- 2013
- Latest Form D
- $25K, Feb 2020
- Total capital
- $9.4M
- Federal grants
- $8M
- 10 awards · 2016–2023
- Rank in peer group#4 of 19
- Private capital raised
- $1.5M
- 3 Form D · last Feb 2020
- 80 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A simulation platform to predict dose and therapeutic window of immunocytokines$300K
- Federal grantHealth and Human S · Phase II · Antibody Drug Conjugate (ADC) Workbench$547K
- Federal grantHealth and Human S · Phase II · Antibody Drug Conjugate (ADC) Workbench$547K
- Federal grantHealth and Human S · Phase II · Antibody Drug Conjugate (ADC) Workbench$1.5M
- Private capital raisedForm D · SEC · 3rd filing$25K
- Federal grantHealth and Human S · Phase I · QSPedia: a curated parameter library to enable the rapid development of quantitative systems pharmacology models$150K
- Federal grantHealth and Human S · Phase II · Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer’s Disease and Dementia.$744K
- Private capital raisedForm D · SEC · 2nd filing$505K
- Private capital raisedForm D · SEC · 1st filing$930K
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.$1.5M
- Federal grantHealth and Human S · Phase II · Development of a robust quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer’s Disease and Dementia.$188K
- Federal grantHealth and Human S · Phase II · A Quantitative Systems Pharmacology Software Platform for Biologics: reduce costs and accelerate development of innovative biotherapeutics$1M
- Federal grantHealth and Human S · Phase II · A Quantitative Systems Pharmacology Software Platform for Biologics reduce costs and accelerate development of innovative biotherapeutics$1.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 19 peers
Line = medianBiotech · Software
- Federal grants#4 · top 21%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Joshua ApgarResearcherDirectorLinked by $2.5M in grants as PI
- Andrew SutherlandDirectorNamed in SEC Form D filings
- John BurkeDirectorNamed in SEC Form D filings
- Peter SorgerDirectorNamed in SEC Form D filings
- Vihann KongDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingMethods And Apparatus For Therapeutic Feasibility Assessment Using Quantitative Systems Pharmacology And Rule-based Reasoning SystemsUSPTOApplication 17713942
- PendingMethods And Apparatus For Therapeutic Feasibility Assessment Using Quantitative Systems Pharmacology And Rule-based Reasoning SystemsUSPTOApplication PCTUS2022023514
- PendingMethod And Apparatus For Therapeutic Feasibility Assessment Using Quantitative Systems PharmacologyUSPTOApplication 63171017
Related companies, and why
- IMMvention Therapeutix, Inc.Similar federal contract value in Biotech · null in contracts
- Regenimo Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Myosin Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Integrated Biotherapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Biomakers, Inc.Similar federal contract value in Biotech · null in contracts
- BOSTON INTERACTOME LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .